

PB60564USw

Remarks

Currently Claims 16-37 are pending. Claims 1-15 are canceled.

Claims 1-9 and 14 are re-written as new claims 16-26 and 29. The claims have been changed to correct clerical errors regarding subscripts in the formulas, to change "represents" to "is", to remove bullet markings and to remove parenthetical expressions. No new matter is added and the scope of the claims is not changed.


Support for new claims 27-28 and 30-31 can be found throughout Applicants' original specification, including at Examples 51 and 1. Support for new claims 32-37 can be found in Applicants' original specification, including at original claim 15 and pages 15-20. No new matter is added.

The title has been amended. The specification has been amended to recite related applications and to provide an abstract on a separate page. No new matter is added.

Entry of the foregoing amendments is respectfully requested.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 3 May 2006
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
Lorie.A.Morgan@gsk.com